噻二唑作为一类新型强效且选择性磷酸二酯酶7（PDE7）抑制剂的发现。第2部分：针对口服生物利用度衍生物的代谢导向优化研究。
Discovery of thiadiazoles as a novel structural class of potent and selective PDE7 inhibitors. Part 2: metabolism-directed optimization studies towards orally bioavailable derivatives.
作者信息
Vergne Fabrice, Bernardelli Patrick, Lorthiois Edwige, Pham Nga, Proust Emmanuelle, Oliveira Chrystelle, Mafroud Abdel-Kader, Ducrot Pierre, Wrigglesworth Roger, Berlioz-Seux Françoise, Coleon Francis, Chevalier Eric, Moreau François, Idrissi Moulay, Tertre Anita, Descours Arnaud, Berna Patrick, Li Mei
机构信息
Pfizer Global Research and Development, 3-9 Rue de la loge 94265 Fresnes, France.
出版信息
Bioorg Med Chem Lett. 2004 Sep 20;14(18):4615-21. doi: 10.1016/j.bmcl.2004.07.009.
PMID:15324875
Abstract
The synthesis and optimization of pharmacokinetic parameters of structurally novel small PDE7 inhibitors is discussed.
摘要
讨论了结构新颖的小分子PDE7抑制剂的药代动力学参数的合成与优化。
相似文献
1
Discovery of thiadiazoles as a novel structural class of potent and selective PDE7 inhibitors. Part 2: metabolism-directed optimization studies towards orally bioavailable derivatives.噻二唑作为一类新型强效且选择性磷酸二酯酶7（PDE7）抑制剂的发现。第2部分：针对口服生物利用度衍生物的代谢导向优化研究。
Bioorg Med Chem Lett. 2004 Sep 20;14(18):4615-21. doi: 10.1016/j.bmcl.2004.07.009.
2
Discovery of thiadiazoles as a novel structural class of potent and selective PDE7 inhibitors. Part 1: design, synthesis and structure-activity relationship studies.噻二唑类作为一类新型强效和选择性磷酸二酯酶7（PDE7）抑制剂的发现。第1部分：设计、合成及构效关系研究。
Bioorg Med Chem Lett. 2004 Sep 20;14(18):4607-13. doi: 10.1016/j.bmcl.2004.07.008.
3
Spiroquinazolinones as novel, potent, and selective PDE7 inhibitors. Part 2: Optimization of 5,8-disubstituted derivatives.螺喹唑啉酮类化合物作为新型、高效且选择性的磷酸二酯酶7（PDE7）抑制剂。第2部分：5,8-二取代衍生物的优化
Bioorg Med Chem Lett. 2004 Sep 20;14(18):4627-31. doi: 10.1016/j.bmcl.2004.07.010.
4
Spiroquinazolinones as novel, potent, and selective PDE7 inhibitors. Part 1.螺喹唑啉酮类化合物作为新型、强效且选择性的磷酸二酯酶7抑制剂。第1部分。
Bioorg Med Chem Lett. 2004 Sep 20;14(18):4623-6. doi: 10.1016/j.bmcl.2004.07.011.
5
Fused pyrimidine based inhibitors of phosphodiesterase 7 (PDE7): synthesis and initial structure-activity relationships.基于稠合嘧啶的磷酸二酯酶7（PDE7）抑制剂：合成及初步构效关系
Bioorg Med Chem Lett. 2005 Apr 1;15(7):1829-33. doi: 10.1016/j.bmcl.2005.02.025.
6
Orally active PDE4 inhibitor with therapeutic potential.
Eur J Med Chem. 2004 Jul;39(7):555-71. doi: 10.1016/j.ejmech.2004.02.010.
7
Substituted 2-pyridinemethanol derivatives as potent and selective phosphodiesterase-4 inhibitors.取代的2-吡啶甲醇衍生物作为强效和选择性磷酸二酯酶-4抑制剂。
Bioorg Med Chem Lett. 2003 Jun 2;13(11):1923-6. doi: 10.1016/s0960-894x(03)00314-7.
8
Potent tetracyclic guanine inhibitors of PDE1 and PDE5 cyclic guanosine monophosphate phosphodiesterases with oral antihypertensive activity.具有口服抗高血压活性的强效四环鸟嘌呤 PDE1 和 PDE5 环磷酸鸟苷磷酸二酯酶抑制剂。
J Med Chem. 1997 Jul 4;40(14):2196-210. doi: 10.1021/jm9608467.
9
The discovery of potent, selective, and orally bioavailable PDE9 inhibitors as potential hypoglycemic agents.发现强效、选择性且口服生物可利用的磷酸二酯酶9（PDE9）抑制剂作为潜在的降血糖药物。
Bioorg Med Chem Lett. 2009 May 1;19(9):2537-41. doi: 10.1016/j.bmcl.2009.03.024. Epub 2009 Mar 13.
10
Selective inhibitors of cyclic AMP-specific phosphodiesterase: heterocycle-condensed purines.环磷酸腺苷特异性磷酸二酯酶的选择性抑制剂：杂环稠合嘌呤。
J Med Chem. 1997 Sep 26;40(20):3248-53. doi: 10.1021/jm970089s.
引用本文的文献
1
Combined use of pharmacophoric models together with drug metabolism and genotoxicity "in silico" studies in the hit finding process.在发现阶段中联合运用药效基团模型和药物代谢及遗传毒性的“计算”研究。
J Comput Aided Mol Des. 2013 Jan;27(1):79-90. doi: 10.1007/s10822-012-9627-1. Epub 2013 Jan 8.
2
Identification in silico and experimental validation of novel phosphodiesterase 7 inhibitors with efficacy in experimental autoimmune encephalomyelitis mice.通过计算机识别和实验验证新型磷酸二酯酶 7 抑制剂在实验性自身免疫性脑脊髓炎小鼠中的疗效。
ACS Chem Neurosci. 2012 Oct 17;3(10):793-803. doi: 10.1021/cn300105c. Epub 2012 Aug 8.
3
Cyclic nucleotide phosphodiesterase (PDE) isozymes as targets of the intracellular signalling network: benefits of PDE inhibitors in various diseases and perspectives for future therapeutic developments.环核苷酸磷酸二酯酶（PDE）同工酶作为细胞内信号网络的靶点：PDE 抑制剂在各种疾病中的益处及未来治疗发展的展望。
Br J Pharmacol. 2012 Mar;165(5):1288-305. doi: 10.1111/j.1476-5381.2011.01729.x.
4
Cyclic nucleotide phosphodiesterase profiling reveals increased expression of phosphodiesterase 7B in chronic lymphocytic leukemia.环核苷酸磷酸二酯酶谱分析显示慢性淋巴细胞白血病中磷酸二酯酶7B的表达增加。
Proc Natl Acad Sci U S A. 2008 Dec 9;105(49):19532-7. doi: 10.1073/pnas.0806152105. Epub 2008 Nov 25.
Zotero 插件